Catalyst Biosciences Current Valuation vs. Total Debt
| CBIODelisted Stock | USD 0.41 0.02 4.65% |
For Catalyst Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Catalyst Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Catalyst Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Catalyst Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Catalyst Biosciences over time as well as its relative position and ranking within its peers.
Catalyst |
Catalyst Biosciences Total Debt vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Catalyst Biosciences's current stock value. Our valuation model uses many indicators to compare Catalyst Biosciences value to that of its competitors to determine the firm's financial worth. Catalyst Biosciences is rated second in current valuation category among its peers. It is rated below average in total debt category among its peers . The ratio of Current Valuation to Total Debt for Catalyst Biosciences is about 1,343 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Catalyst Biosciences' earnings, one of the primary drivers of an investment's value.Catalyst Current Valuation vs. Competition
Catalyst Biosciences is rated second in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 250.84 Million. Catalyst Biosciences totals roughly 51.03 Million in current valuation claiming about 20% of equities under Health Care industry.
Catalyst Total Debt vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Catalyst Biosciences |
| = | 51.03 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Catalyst Biosciences |
| = | 38 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Catalyst Total Debt vs Competition
Catalyst Biosciences is rated below average in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 18.7 Million. Catalyst Biosciences adds roughly 38,000 in total debt claiming only tiny portion of equities under Health Care industry.
Catalyst Biosciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Catalyst Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Catalyst Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of Catalyst Biosciences' change in net profit over the period of time. It can combine multiple indicators of Catalyst Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California. Catalyst Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 45 people.
Catalyst Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Catalyst Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Catalyst Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Catalyst Biosciences' important profitability drivers and their relationship over time.
Use Catalyst Biosciences in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Catalyst Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catalyst Biosciences will appreciate offsetting losses from the drop in the long position's value.Catalyst Biosciences Pair Trading
Catalyst Biosciences Pair Trading Analysis
The ability to find closely correlated positions to Catalyst Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Catalyst Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Catalyst Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Catalyst Biosciences to buy it.
The correlation of Catalyst Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Catalyst Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Catalyst Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Catalyst Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Catalyst Biosciences position
In addition to having Catalyst Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Monster Funds Thematic Idea Now
Monster Funds
Solid funds with above average long term performance indicators based on Macroaxis rating system. The Monster Funds theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Monster Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in Catalyst Stock
If you are still planning to invest in Catalyst Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catalyst Biosciences' history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |